Predictors of mortality in Parkinson's disease and the development of a prognostic model

Abstract Background Most previous prognostic studies in Parkinson's disease have used unrepresentative cohorts with selection biases resulting in major heterogeneity in estimates of mortality. Prognosis is best studied by long-term follow-up of community-based incident cohorts. Prognostic model...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2016-02, Vol.387, p.S67-S67
Hauptverfasser: Macleod, Angus D, Dr, Counsell, Carl E, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S67
container_issue
container_start_page S67
container_title The Lancet (British edition)
container_volume 387
creator Macleod, Angus D, Dr
Counsell, Carl E, MD
description Abstract Background Most previous prognostic studies in Parkinson's disease have used unrepresentative cohorts with selection biases resulting in major heterogeneity in estimates of mortality. Prognosis is best studied by long-term follow-up of community-based incident cohorts. Prognostic models can predict a patient's risk and improve clinical trial design, but none has been published for use in Parkinson's disease. We aimed to describe mortality in this disorder, identify independent prognostic factors, and develop a valid prognostic model. Methods All incident cases of Parkinson's disease in Aberdeen, UK (Nov 1, 2002, to April 30, 2004, and April 1, 2006, to March 31, 2009) identified with multiple, community-based ascertainment strategies were followed prospectively with death notification from the National Health Service central register. Mortality rates and age-adjusted and sex-adjusted standardised mortality ratios (SMRs) were calculated with indirect standardisation to regional mortality data. Weibull regression was used to create a prognostic model with clinical predictors measured at diagnosis and validated internally. Findings 198 incident cases of Parkinson's disease were identified. 91 of these 198 patients died after follow-up of up to 12 years (mean 6·1, SD 2·4). No losses to follow-up occurred. The mortality rate was 8·1 deaths per 100 person-years (95% CI 6·6–9·9) and was increased by 50% over those without Parkinson's disease (SMR 1·51, 95% CI 1·22–1·87). Independent baseline prognostic factors for increasing mortality were age (hazard ratio for 10 year increase 1·91, 1·43–2·54), male sex (1·84, 1·17–2·91), more bradykinesia (5 point increase 1·40, 1·14–1·72), more axial relative to limb features (1 unit increase in axial to limb ratio 1·81, 1·22–2·68), and comorbidity (1 unit increase in Charlson score 1·33, 1·14–1·56). A prognostic model incorporating these prognostic factors had good discrimination (Harrel's C-statistic=0·84) and calibration. An electronic predictive risk calculator was created. Interpretation This estimate of mortality is greater than many previous estimates, probably because we used a more representative cohort with a higher proportion of frail and elderly people than in most previous studies. Identification of prognostic factors and their combination in a prognostic model will allow individualised risk prediction, and facilitate stratified medicine and improved clinical trial design. Further work will include extern
doi_str_mv 10.1016/S0140-6736(16)00454-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837338625</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673616004542</els_id><sourcerecordid>3966389691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2652-a4ec9829fdbdfb7608151d46b814aa7d7e916a34cc9f5490373578d33cd9bd623</originalsourceid><addsrcrecordid>eNqFkF1rFDEUhoMouFZ_ghDwwnoxmkw-50YpRVuhYEGF3oVsckbTziZrzmxh_72ZXVHojVfhwPM-vHkJecnZW864fveVcck6bYQ-5foNY1LJrn9EVlwa2Slpbh6T1V_kKXmGeMsapZlakZvrCjGFuVSkZaSbUmc_pXlPU6bXvt6ljCW_RhoTgkegPkc6_wQa4R6mst1Anpecp9tafuSCcwpNEmF6Tp6MfkJ48ec9Id8_ffx2ftldfbn4fH521YVeq77zEsJg-2GM6ziujWaWKx6lXlsuvTfRwMC1FzKEYVRyYMIIZWwUIsRhHXUvTsjp0dsK_NoBzm6TMMA0-Qxlh47bFhFW96qhrx6gt2VXc2vnuNFWWW0H3ih1pEItiBVGt61p4-veceaWvd1hb7eM6dp12NstRT4cc9B-e5-gOgwJcmjzVgiziyX91_D-gSFMKafgpzvYA_4r67B37ChZHFwfDL34DX3Pm5s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1768586891</pqid></control><display><type>article</type><title>Predictors of mortality in Parkinson's disease and the development of a prognostic model</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Macleod, Angus D, Dr ; Counsell, Carl E, MD</creator><creatorcontrib>Macleod, Angus D, Dr ; Counsell, Carl E, MD</creatorcontrib><description>Abstract Background Most previous prognostic studies in Parkinson's disease have used unrepresentative cohorts with selection biases resulting in major heterogeneity in estimates of mortality. Prognosis is best studied by long-term follow-up of community-based incident cohorts. Prognostic models can predict a patient's risk and improve clinical trial design, but none has been published for use in Parkinson's disease. We aimed to describe mortality in this disorder, identify independent prognostic factors, and develop a valid prognostic model. Methods All incident cases of Parkinson's disease in Aberdeen, UK (Nov 1, 2002, to April 30, 2004, and April 1, 2006, to March 31, 2009) identified with multiple, community-based ascertainment strategies were followed prospectively with death notification from the National Health Service central register. Mortality rates and age-adjusted and sex-adjusted standardised mortality ratios (SMRs) were calculated with indirect standardisation to regional mortality data. Weibull regression was used to create a prognostic model with clinical predictors measured at diagnosis and validated internally. Findings 198 incident cases of Parkinson's disease were identified. 91 of these 198 patients died after follow-up of up to 12 years (mean 6·1, SD 2·4). No losses to follow-up occurred. The mortality rate was 8·1 deaths per 100 person-years (95% CI 6·6–9·9) and was increased by 50% over those without Parkinson's disease (SMR 1·51, 95% CI 1·22–1·87). Independent baseline prognostic factors for increasing mortality were age (hazard ratio for 10 year increase 1·91, 1·43–2·54), male sex (1·84, 1·17–2·91), more bradykinesia (5 point increase 1·40, 1·14–1·72), more axial relative to limb features (1 unit increase in axial to limb ratio 1·81, 1·22–2·68), and comorbidity (1 unit increase in Charlson score 1·33, 1·14–1·56). A prognostic model incorporating these prognostic factors had good discrimination (Harrel's C-statistic=0·84) and calibration. An electronic predictive risk calculator was created. Interpretation This estimate of mortality is greater than many previous estimates, probably because we used a more representative cohort with a higher proportion of frail and elderly people than in most previous studies. Identification of prognostic factors and their combination in a prognostic model will allow individualised risk prediction, and facilitate stratified medicine and improved clinical trial design. Further work will include external validation in an international cohort. Funding Chief Scientist Office of the Scottish Government, Parkinson's UK.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(16)00454-2</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Heterogeneity ; Internal Medicine ; Mortality ; Parkinson's disease</subject><ispartof>The Lancet (British edition), 2016-02, Vol.387, p.S67-S67</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Feb 25, 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1768586891?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids></links><search><creatorcontrib>Macleod, Angus D, Dr</creatorcontrib><creatorcontrib>Counsell, Carl E, MD</creatorcontrib><title>Predictors of mortality in Parkinson's disease and the development of a prognostic model</title><title>The Lancet (British edition)</title><description>Abstract Background Most previous prognostic studies in Parkinson's disease have used unrepresentative cohorts with selection biases resulting in major heterogeneity in estimates of mortality. Prognosis is best studied by long-term follow-up of community-based incident cohorts. Prognostic models can predict a patient's risk and improve clinical trial design, but none has been published for use in Parkinson's disease. We aimed to describe mortality in this disorder, identify independent prognostic factors, and develop a valid prognostic model. Methods All incident cases of Parkinson's disease in Aberdeen, UK (Nov 1, 2002, to April 30, 2004, and April 1, 2006, to March 31, 2009) identified with multiple, community-based ascertainment strategies were followed prospectively with death notification from the National Health Service central register. Mortality rates and age-adjusted and sex-adjusted standardised mortality ratios (SMRs) were calculated with indirect standardisation to regional mortality data. Weibull regression was used to create a prognostic model with clinical predictors measured at diagnosis and validated internally. Findings 198 incident cases of Parkinson's disease were identified. 91 of these 198 patients died after follow-up of up to 12 years (mean 6·1, SD 2·4). No losses to follow-up occurred. The mortality rate was 8·1 deaths per 100 person-years (95% CI 6·6–9·9) and was increased by 50% over those without Parkinson's disease (SMR 1·51, 95% CI 1·22–1·87). Independent baseline prognostic factors for increasing mortality were age (hazard ratio for 10 year increase 1·91, 1·43–2·54), male sex (1·84, 1·17–2·91), more bradykinesia (5 point increase 1·40, 1·14–1·72), more axial relative to limb features (1 unit increase in axial to limb ratio 1·81, 1·22–2·68), and comorbidity (1 unit increase in Charlson score 1·33, 1·14–1·56). A prognostic model incorporating these prognostic factors had good discrimination (Harrel's C-statistic=0·84) and calibration. An electronic predictive risk calculator was created. Interpretation This estimate of mortality is greater than many previous estimates, probably because we used a more representative cohort with a higher proportion of frail and elderly people than in most previous studies. Identification of prognostic factors and their combination in a prognostic model will allow individualised risk prediction, and facilitate stratified medicine and improved clinical trial design. Further work will include external validation in an international cohort. Funding Chief Scientist Office of the Scottish Government, Parkinson's UK.</description><subject>Heterogeneity</subject><subject>Internal Medicine</subject><subject>Mortality</subject><subject>Parkinson's disease</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkF1rFDEUhoMouFZ_ghDwwnoxmkw-50YpRVuhYEGF3oVsckbTziZrzmxh_72ZXVHojVfhwPM-vHkJecnZW864fveVcck6bYQ-5foNY1LJrn9EVlwa2Slpbh6T1V_kKXmGeMsapZlakZvrCjGFuVSkZaSbUmc_pXlPU6bXvt6ljCW_RhoTgkegPkc6_wQa4R6mst1Anpecp9tafuSCcwpNEmF6Tp6MfkJ48ec9Id8_ffx2ftldfbn4fH521YVeq77zEsJg-2GM6ziujWaWKx6lXlsuvTfRwMC1FzKEYVRyYMIIZWwUIsRhHXUvTsjp0dsK_NoBzm6TMMA0-Qxlh47bFhFW96qhrx6gt2VXc2vnuNFWWW0H3ih1pEItiBVGt61p4-veceaWvd1hb7eM6dp12NstRT4cc9B-e5-gOgwJcmjzVgiziyX91_D-gSFMKafgpzvYA_4r67B37ChZHFwfDL34DX3Pm5s</recordid><startdate>20160225</startdate><enddate>20160225</enddate><creator>Macleod, Angus D, Dr</creator><creator>Counsell, Carl E, MD</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20160225</creationdate><title>Predictors of mortality in Parkinson's disease and the development of a prognostic model</title><author>Macleod, Angus D, Dr ; Counsell, Carl E, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2652-a4ec9829fdbdfb7608151d46b814aa7d7e916a34cc9f5490373578d33cd9bd623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Heterogeneity</topic><topic>Internal Medicine</topic><topic>Mortality</topic><topic>Parkinson's disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Macleod, Angus D, Dr</creatorcontrib><creatorcontrib>Counsell, Carl E, MD</creatorcontrib><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Macleod, Angus D, Dr</au><au>Counsell, Carl E, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of mortality in Parkinson's disease and the development of a prognostic model</atitle><jtitle>The Lancet (British edition)</jtitle><date>2016-02-25</date><risdate>2016</risdate><volume>387</volume><spage>S67</spage><epage>S67</epage><pages>S67-S67</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Abstract Background Most previous prognostic studies in Parkinson's disease have used unrepresentative cohorts with selection biases resulting in major heterogeneity in estimates of mortality. Prognosis is best studied by long-term follow-up of community-based incident cohorts. Prognostic models can predict a patient's risk and improve clinical trial design, but none has been published for use in Parkinson's disease. We aimed to describe mortality in this disorder, identify independent prognostic factors, and develop a valid prognostic model. Methods All incident cases of Parkinson's disease in Aberdeen, UK (Nov 1, 2002, to April 30, 2004, and April 1, 2006, to March 31, 2009) identified with multiple, community-based ascertainment strategies were followed prospectively with death notification from the National Health Service central register. Mortality rates and age-adjusted and sex-adjusted standardised mortality ratios (SMRs) were calculated with indirect standardisation to regional mortality data. Weibull regression was used to create a prognostic model with clinical predictors measured at diagnosis and validated internally. Findings 198 incident cases of Parkinson's disease were identified. 91 of these 198 patients died after follow-up of up to 12 years (mean 6·1, SD 2·4). No losses to follow-up occurred. The mortality rate was 8·1 deaths per 100 person-years (95% CI 6·6–9·9) and was increased by 50% over those without Parkinson's disease (SMR 1·51, 95% CI 1·22–1·87). Independent baseline prognostic factors for increasing mortality were age (hazard ratio for 10 year increase 1·91, 1·43–2·54), male sex (1·84, 1·17–2·91), more bradykinesia (5 point increase 1·40, 1·14–1·72), more axial relative to limb features (1 unit increase in axial to limb ratio 1·81, 1·22–2·68), and comorbidity (1 unit increase in Charlson score 1·33, 1·14–1·56). A prognostic model incorporating these prognostic factors had good discrimination (Harrel's C-statistic=0·84) and calibration. An electronic predictive risk calculator was created. Interpretation This estimate of mortality is greater than many previous estimates, probably because we used a more representative cohort with a higher proportion of frail and elderly people than in most previous studies. Identification of prognostic factors and their combination in a prognostic model will allow individualised risk prediction, and facilitate stratified medicine and improved clinical trial design. Further work will include external validation in an international cohort. Funding Chief Scientist Office of the Scottish Government, Parkinson's UK.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(16)00454-2</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 2016-02, Vol.387, p.S67-S67
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_miscellaneous_1837338625
source Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland
subjects Heterogeneity
Internal Medicine
Mortality
Parkinson's disease
title Predictors of mortality in Parkinson's disease and the development of a prognostic model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A39%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20mortality%20in%20Parkinson's%20disease%20and%20the%20development%20of%20a%20prognostic%20model&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Macleod,%20Angus%20D,%20Dr&rft.date=2016-02-25&rft.volume=387&rft.spage=S67&rft.epage=S67&rft.pages=S67-S67&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(16)00454-2&rft_dat=%3Cproquest_cross%3E3966389691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1768586891&rft_id=info:pmid/&rft_els_id=S0140673616004542&rfr_iscdi=true